Explore Our Areas

Latest News

Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology

FLORENCE, Italy and NEW YORK, Nov. 20, 2023 -- The Menarini Group ("Menarini"), a leading Italian pharmaceutical and diagnostics company, and Stemline...

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

FLORENCE (Italy) and HONG KONG (China), November 7, 2023 – The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and SciClone...

European Organisation for Research and Treatment of Cancer & the Menarini Group Launch New Clinical Trial in Early-Stage Breast Cancer

Brussels (Belgium) and Florence (Italy), 19 October 2023 – The European Organisation for Research and Treatment of Cancer (EORTC) and the Menarini Group (Menarini), a leading...

Search Menarini in the world

v

Etiam commodo dui eget wisi. Donec iaculis gravida nulla. Donec quis nibh at felis congue commodo. Etiam bibendum elit eget erat.

Use the key combination "ctrl" + "mouse wheel" or the "+" and "-" buttons at the bottom right to browse the map



menarini for people

Discover our responsibility projects to stand close to people

read more

Follow our blog

Discover our stories from all over the world

Read More

fondazione internazionale menarini

a meeting point for all friends with common ideals towards the progress of sciences for the benefit of mankind.

sergio gorini, foundation’s first president

read more